Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Royalty Pharma PLC (RPRX)
NASDAQ:RPRX
RPRX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$24.05 - $32.89
Previous CloseN/A
Volume726.99K
Average Volume (3M)4.21M
Market Cap
$18.66B
Enterprise Value$26.77B
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)16.9
Beta0.42
Next Earnings
May 07, 2025EPS Estimate
1.12Next Dividend Ex-Date
Feb 21, 2025Dividend Yield2.6%
Share Statistics
EPS (TTM)1.92
Shares Outstanding433,324,900
10 Day Avg. Volume4,002,512
30 Day Avg. Volume4,209,700
Standard Deviation0.07
R-Squared0.11
Alpha-0.01
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)8.24
Price to Cash Flow (P/CF)6.30
P/FCF Ratio6.30
Enterprise Value/Market Cap1.43
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit11.82
Enterprise Value/Ebitda14.59
Forecast
1Y Price Target
$41.00Price Target Upside26.70% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
---
Royalty Pharma News
PremiumCompany Announcements
Royalty Pharma PLC Reports Strong 2024 Financial Results
PremiumCompany Announcements
Royalty Pharma’s Optimistic Earnings Call Highlights Growth---
Bulls Say, Bears Say
Bulls Say
Management And Shareholder AlignmentThe move to internalize the manager simplifies financial reporting and provides clear alignment between management and shareholders.
Revenue GrowthRoyalty Pharma's execution is impressive with solid mid-teens recurring revenue growth and prudent capital deployment.
Share Buyback ProgramA $3B share buyback program boosts EPS and exemplifies management confidence.
Bears Say
Management ControlMembers of the Board of Directors and management who control approximately 25% of the fully diluted shares have agreed to vote in favor of the transaction.
Share OwnershipThe bigger concern, however, is the 80% shares owned by management post the 2025 lock-up period.
Stock PerformanceRPRX shares have underperformed the biotech index benchmark YTD.
---
Ownership Overview
0.72% Insiders
17.37% Mutual Funds
11.61% Other Institutional Investors
55.31% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
RPRX FAQ
What was Royalty Pharma PLC’s price range in the past 12 months?
Royalty Pharma PLC lowest stock price was $24.05 and its highest was $32.89 in the past 12 months.
What is Royalty Pharma PLC’s market cap?
Royalty Pharma PLC’s market cap is $18.66B.
When is Royalty Pharma PLC’s upcoming earnings report date?
Royalty Pharma PLC’s upcoming earnings report date is May 07, 2025 which is in 79 days.
How were Royalty Pharma PLC’s earnings last quarter?
Royalty Pharma PLC released its earnings results on Feb 11, 2025. The company reported $1.151 earnings per share for the quarter, beating the consensus estimate of $1.055 by $0.096.
Is Royalty Pharma PLC overvalued?
According to Wall Street analysts Royalty Pharma PLC’s price is currently Undervalued.
Does Royalty Pharma PLC pay dividends?
Royalty Pharma PLC pays a Quarterly dividend of $0.219 which represents an annual dividend yield of 2.6%. See more information on Royalty Pharma PLC dividends here
What is Royalty Pharma PLC’s EPS estimate?
Royalty Pharma PLC’s EPS estimate is 1.12.
How many shares outstanding does Royalty Pharma PLC have?
Royalty Pharma PLC has 433,324,900 shares outstanding.
What happened to Royalty Pharma PLC’s price movement after its last earnings report?
Royalty Pharma PLC reported an EPS of $1.151 in its last earnings report, beating expectations of $1.055. Following the earnings report the stock price went up 1.671%.
Which hedge fund is a major shareholder of Royalty Pharma PLC?
Among the largest hedge funds holding Royalty Pharma PLC’s share is Viking Global Investors LP. It holds Royalty Pharma PLC’s shares valued at 342M.
---
Royalty Pharma Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$41.00 (26.70% Upside)
$41.00 (26.70% Upside)
Blogger Sentiment
Bullish
RPRX Sentiment 80%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 493.1K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.0%
Last 30 Days ▼ 5.7%
Last 30 Days ▼ 5.7%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
13.87%
12-Months-Change
Fundamentals
Return on Equity
12.75%
Trailing 12-Months
Asset Growth
11.24%
Trailing 12-Months
Company Description
Royalty Pharma PLC
New York-based Royalty Pharma Plc is a biopharmaceutical company, which is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry.
---
RPRX Company Deck
---
RPRX Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call for Royalty Pharma presents a positive outlook with significant portfolio growth, strategic FDA approvals, strong capital deployment, and the internalization transaction poised to deliver substantial future savings. Despite some challenges, such as the impact of onetime Biohaven payments and potential interest expense increases, the company's robust financial performance and strategic initiatives suggest a strong position for future growth.Read More>---
RPRX Revenue Breakdown
93.34% Income from financial royalty assets
6.62% Other royalty income
0.04% Revenue from intangible royalty assets
---
RPRX Stock 12 Month Forecast
Average Price Target
$41.00
▲(26.70% Upside)
Technical Analysis
Best Analysts Covering RPRX
1 Year
1 Year Success Rate
5/10 ratings generated profit
1 Year Average Return
-2.06%
reiterated a buy rating 6 months ago
Copying Chris Shibutani's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of -2.06% per trade.
---